Can-Fite BioPharma heads into the week with short sellers in full retreat — a dramatic reversal from a peak that coincided almost exactly with its most important clinical readout in years.
The positioning story over the past fortnight has been striking. Short interest climbed from under 0.5% of the free float in late April to a peak of nearly 13% on May 5 — a 25-fold increase in less than a week, timed around the April 30 release of Phase 2a pancreatic cancer data for its lead drug namodenoson. That spike has since collapsed just as fast. By May 12, estimated short interest had fallen back to 0.5% of the float — essentially where it was before the trial readout. The move looks less like a sustained bearish thesis and more like speculative positioning around a binary clinical event, which has now largely unwound.
The clinical data itself appears to be what triggered the reassessment. Can-Fite reported that 35% of patients in the namodenoson pancreatic cancer study remained on therapy, including one beyond 16 months, with stable disease observed in over 30% of patients and a favourable safety profile. More importantly, the company announced on May 13 it will advance namodenoson into a Phase 2b study in combination with immunotherapy. That step-up in programme ambition landed with analysts. HC Wainwright maintained its Buy rating and raised its price target to $5, acting on May 12. The following day, D. Boral Capital upgraded the stock to Buy with a $7 price target. Both moves are very fresh — within the past 48 hours — and represent a clear directional shift on the Street toward the upside case.
The bull argument now centres on the Phase 2b combination study, where namodenoson's A3 adenosine receptor mechanism may complement checkpoint inhibitor therapy in a tumour type that has historically resisted immunotherapy. The bear case rests on the realities facing any micro-cap Israeli biotech: Can-Fite carries a market cap of roughly $7 million, the balance sheet bears watching, and Phase 2b success is far from guaranteed. Institutional ownership is thin — the top eight reported holders together hold less than 2.5% of shares, with Orca Capital the largest at just over 1.2%. Factor scores are unremarkable, with a dividend score of 32 and a sector score of 50, reflecting no meaningful edge in capital return or relative sector positioning.
The next formal earnings event is pencilled in for August 26. Prior results releases have generated muted immediate price reactions — moves of around 1–2% on the day — though five-day drifts have been slightly negative in recent quarters. That pattern matters less here than the clinical calendar: the Phase 2b study design, enrolment timeline, and any interim data will set the narrative between now and year-end.
What to watch is whether the analyst re-rating — two Buy upgrades in two days from firms that cover the stock closely — translates into any sustained improvement in the share price, which remains near ILS 4.8 and is down about 1% on the month despite the clinical news. The short interest data shows the most aggressive positioning has already cleared; the next test for CANF is whether the Phase 2b announcement can hold the attention of a market that briefly paid close attention, then moved on.
See the live data behind this article on ORTEX.
Open CANF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
